| Features: |
| Myricetin is a naturally occurring flavonoid that has been the subject of extensive preclinical studies for its potential anticancer properties. Pathways: -Inhibit the PI3K/Akt signaling pathway, which is often hyperactive in many cancers -MAPK/ERK Pathway -Inhibit NF‑κB activation -Activate or enhance p53 signaling, thereby contributing to its anticancer effects -AK/STAT Signaling -May inhibit angiogenesis (VEGF) -Suppress the processes involved in metastasis, such as matrix metalloproteinase (MMP) activity -Can exert antioxidant effects; however, in cancer cells, it sometimes induces oxidative stress beyond a threshold, contributing to apoptotic cell death. -Inhibitory effects on mammalian TrxRs (thioredoxin reductase) |
| 1044- | Myr, | Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 1128- | Myr, | Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer |
| - | vitro+vivo, | Ovarian, | NA |
| 1141- | Myr, | Myricetin: targeting signaling networks in cancer and its implication in chemotherapy |
| - | Review, | NA, | NA |
| 1273- | Myr, | Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4 |
| - | vitro+vivo, | GC, | NA |
| 1997- | Myr, | QC, | Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity |
| - | in-vitro, | Lung, | A549 |
| 1998- | Myr, | CUR, | Thioredoxin-dependent system. Application of inhibitors |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:127 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid